What's happened
The NHS has rejected the Alzheimer's drug donanemab, citing insufficient value for patients despite its recent licensing in the UK. This marks the second disease-modifying Alzheimer's treatment turned down by NICE in months, raising concerns about the UK's position in dementia treatment development.
Why it matters
What the papers say
According to The Guardian, the NHS's rejection of donanemab was based on its assessment that the drug does not provide sufficient benefits to justify its high cost. Helen Knight, director of medicines evaluation at NICE, stated, "The cost-effectiveness estimate for donanemab is five to six times above what NICE normally considers an acceptable use of NHS resources." In contrast, Alzheimer’s Research UK expressed disappointment, warning that this decision could signal that the UK is no longer a favorable environment for launching new dementia treatments. Ella Pickover from The Independent highlighted that while donanemab showed some efficacy in slowing cognitive decline, the associated risks and costs led to its rejection. This sentiment was echoed by other sources, emphasizing the need for more effective and safer treatments to emerge from ongoing research efforts.
How we got here
Donanemab, developed by Eli Lilly, was recently licensed for use in the UK but has been rejected by the National Institute for Health and Care Excellence (NICE) due to concerns over its cost-effectiveness and limited benefits. This follows a similar rejection of another Alzheimer's drug, lecanemab, earlier this year.
Common question
-
What is the new laser-based technique for diagnosing dementia?
Recent advancements in dementia diagnosis are making headlines, particularly a groundbreaking laser-based technique developed by researchers at the University of Southampton. This method promises to diagnose dementia in seconds with remarkable accuracy. But what does this mean for patients and the future of dementia treatment? Here are some key questions and answers about this innovative approach and its implications.
-
How Does Climate Change Affect Marine Life and Ecosystems?
Climate change poses a significant threat to marine ecosystems, impacting biodiversity and carbon storage. Understanding these effects is crucial for conservation efforts and the health of our oceans. Below, we explore common questions about the relationship between climate change and marine life.
-
What Are the Latest Innovations in Dementia Care?
Dementia care is evolving rapidly with new advancements in diagnosis and treatment. As researchers explore innovative methods, many are left wondering how these changes could impact the lives of patients and their families. Here are some common questions about the latest developments in dementia care.
-
Will Longer Sentences Deter Crime in the UK?
With magistrates in England and Wales set to gain new sentencing powers allowing them to impose custodial sentences of up to 12 months, many are questioning the potential impact on crime rates. This change aims to address the significant backlog in crown courts and reduce the number of remand prisoners. However, concerns about overcrowding and the effectiveness of longer sentences in deterring crime remain prevalent. Below, we explore key questions surrounding this significant shift in the UK justice system.
-
How is AI Changing Climate Action Compared to Traditional Methods?
As the climate crisis intensifies, the debate over the role of AI in climate action versus traditional methods is heating up. While some argue that AI offers innovative solutions, others emphasize the importance of implementing existing technologies. This page explores the key questions surrounding this critical issue.
-
What Are the Latest Advances in Dementia Research?
Dementia research is rapidly evolving, with new studies revealing innovative methods for diagnosis and treatment. Understanding these advancements can help families and caregivers navigate the complexities of dementia care. Here are some common questions about the latest findings in dementia research.
-
Why Did NICE Reject the Alzheimer's Drug Donanemab?
The recent decision by NICE to reject the Alzheimer's drug donanemab has raised many questions among patients, families, and healthcare professionals. Understanding the reasons behind this rejection, the implications for Alzheimer's treatment, and the alternatives available is crucial for those affected by this devastating disease.
-
Why Did the NHS Reject the New Alzheimer's Drug Donanemab?
The recent rejection of the Alzheimer's drug donanemab by the NHS has raised significant concerns among patients and healthcare advocates. With the drug recently licensed in the UK, many are left wondering why it was turned down and what this means for the future of dementia treatment in the country. Below, we explore the reasons behind this decision and its implications for Alzheimer's patients.
-
Why Did the NHS Reject the Alzheimer's Drug Donanemab?
The recent rejection of the Alzheimer's drug donanemab by the NHS has raised significant concerns among patients and healthcare professionals alike. This decision not only impacts those living with dementia but also highlights the broader implications for Alzheimer's treatment in the UK. Below, we explore the reasons behind this decision and what it means for the future of dementia care.
More on these topics
-
Donanemab is a biological drug in trial to treat early symptoms of Alzheimer's disease. There is no cure or treatment for Alzheimer’s disease. Donanemab has shown positive results in Eli Lilly and Co.’s first two trials.
-
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a
-
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion to patients with mild cognitive impairmen
-
The National Institute for Health and Care Excellence is an executive non-departmental public body of the Department of Health in England, which publishes guidelines in four areas:
-
Nice is the seventh most populous urban area in France and the capital of the Alpes-Maritimes department. The metropolitan area of Nice extends beyond the administrative city limits, with a population of about 1 million on an area of 721 km².
-
The Medicines and Healthcare products Regulatory Agency is an executive agency of the Department of Health and Social Care in the United Kingdom which is responsible for ensuring that medicines and medical devices work and are acceptably safe.
-
The United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom or Britain, is a sovereign country located off the northwestern coast of the European mainland.
-
The University of Southampton is a research university in Southampton, England. The university's origins date back to the founding of the Hartley Institution in 1862.